Sibeprenlimab Reference: HY-P99901 Sibeprenlimab (VIS649) is a humanized IgG2 monoclonal antibody. Sibeprenlimab can inhibit APRIL. Sibeprenlimab can be used for the research of IgA nephropathy (IgAN).
Organelle Marker Antibody Panel Reference: GTX300001 Poly(ADP-ribosyl)transferase (PARP1) is a chromatin-associated enzyme, which modifies various nuclear proteins by poly(ADP-ribosyl)ation. This antibody is a control for nuclear localization. PARP1 has a molecular weight of 113 kDa. Alpha-tubulin is one of the two the major structural components of microtubules, part of the eukaryotic cytoskeleton. The alpha-tubulin 4a subunit is a highly conserved among species. This antibody is a control for cytoplasmic localization. Alpha-tubulin has a molecular weight of 5 kDa. Calnexin is a calcium-binding molecular chaperone protein that plays a critical role in N-glycosylation of proteins. Calnexin is localized to the endoplasmic reticulum (ER) and has a predicted molecular weight of 66 kDa. Aldo-keto reductase family 7 (AKR7) is an enzyme involved in the detoxification of aldehydes and ketones. It is localized to the golgi apparatus and has a predicted molecular weight of 4 kDa. NHP2-like protein 1 is a highly conserved nuclear protein that is a component of the [U4/U6.U5] tri-snRNP. It is localized to the nucleolus and has a predicted molecular weight of 14 kDa
Tengonermin Reference: HY-P99565 Tengonermin (ARENEGYR) is a vascular-targeting agent consisting of the human Tumour Necrosis Factor-α (TNF-α) conjugated with the CNGRCG peptide. Tengonermin increases penetration of intratumoral chemotherapy and T-cell infiltration by modifying the tumour microenvironment.
Tinurilimab Reference: HY-P99051 Tinurilimab (Bay 1834942) is an anti-CEACAM6 monoclonal antibody. CEACAM6 is an immune checkpoint regulator suppressing the activity of effector T-cells against tumors.
Ralpancizumab Reference: HY-P99816 Ralpancizumab is a selective PCSK9 inhibitor with potential application in hemorrhagic stroke.
Glenzocimab Reference: HY-P99644 Glenzocimab (ACT017) is a Fab fragment of humanized anti-GPVI monoclonal antibody. Glenzocimab inhibits collagen-induced platelet aggregation. Glenzocimab has the potential for the research of acute ischemic stroke.
Pepinemab Reference: HY-P99407 Pepinemab (VX 15/2503) is a human monoclonal antibody against SEMA4D, a signalling protein 4D (SEMA4D), also known as CD100, which is a regulator of neuronal development and plays a role in a variety of cellular processes. Pepinemab can be used in the study of various neurodegenerative diseases such as Alzheimer's disease by blocking the activity of SEMA4D.